CD33-positive acute myeloid leukemia (AML) | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Acute myeloid leukaemia (AML) is a cancer of the blood and bone marrow. AML is not brought on by any illness. It is the name given to a group of leukemias that develop from the myeloid cell line in the bone marrow. Myeloid cells are all white blood cells other than lymphocytes, including red blood cells, platelets, and other types of white blood cells. 2022 is expected to see 20,050 new cases of AML in the nation (11,140 in men and 8910 in women), according to the American Cancer Society (ACS). White people are more likely than other racial or ethnic groups to receive an AML diagnosis, which occurs more frequently in industrialized countries.

Description

Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow. AML isn't triggered by any one thing. It is the term used to designate a group of leukemias that develop from the bone marrow's myeloid cell line. Myeloid cells are all white blood cells other than lymphocytes, including red blood cells, platelets, and other types of white blood cells. AML is characterized by myeloblasts, also known as leukemic blasts or excessive production of immature white blood cells. These cells clog the bone marrow, preventing it from producing healthy blood cells. In addition, they might get out and move through the blood, circulating all over the body. They lack the maturity to effectively fight or prevent infection. The bone marrow's inability to produce enough red blood cells and platelets can cause anaemia, bruising, and/or easy bleeding.

CD33-positive acute myeloid leukemia (AML) (Epidemiology)

According to the American Cancer Society (ACS), there will be 20,050 new cases of AML in the nation in 2022 (11,140 of them will be in men and 8910 will be in women). White people are more likely to be diagnosed with AML than people of other racial or ethnic groups. AML diagnoses are more common in industrialized countries. As people age, AML becomes more typical. The average age of onset is around 70. But AML can affect people of all ages. AML is more common in men than in women, especially in older people. This is most likely due to the fact that severe MDS frequently develops into AML and that MDS is more common in men. AML in males is more common than it is in females, and some have speculated that occupational exposures may be to blame.

CD33-positive acute myeloid leukemia (AML) -Current Market Size & Forecast Trends

The market for CD33-positive acute myeloid leukemia (AML) is part of the broader acute myeloid leukemia treatment market, which was valued at approximately USD 3.41 billion in 2024 and is projected to reach around USD 12.63 billion by 2037, growing at a CAGR of 10.6% during this period. The increasing incidence of AML, particularly among the aging population, along with advancements in treatment options such as targeted therapies and immunotherapies, are key drivers of this growth. Notably, therapies targeting CD33, such as gemtuzumab ozogamicin, are gaining traction in clinical settings, contributing to the overall market expansion. North America is expected to maintain a significant share of the market due to ongoing research and development efforts and a high prevalence of AML cases. As new therapies are developed and approved, the market for CD33-positive AML is likely to continue its upward trend through 2035.

The treatments for acute myeloid leukemia (AML) are evolving constantly in response to the rise in blood cancer cases. The past ten years have seen an increase in the incidence of acute myeloid leukemia. A person's risk of developing bone marrow cancer increases with age. Women and men are now both more likely to develop it between the ages of 75 and 84. More children with leukemia now have acute myeloid leukaemia, which is more prevalent, especially in newborns. Changing demographics and living conditions lead to the adoption of harmful behaviors. The increasing demand for sophisticated therapies for acute myeloid leukaemia early diagnosis and treatment is thus one of the lucrative prospects for market expansion. Patients are more likely to use these treatments in order to increase their chances of survival. Technical advancements in medicine have led to faster turnaround times and higher recovery rates. The pricey therapy equipment and its side effects, however, severely restrict the market's growth. Inconsistent reimbursement policies and stringent guidelines for product approval are two additional challenges facing the acute myeloid leukemia (AML) therapies market. AB 8939 (AB Science), DCP-001 (DCPrime), Clifutinib besylate (HEC Pharm), and other well-known brands are available on the market for medications for acute myeloid leukemia (AML).

Report Highlights

CD33-positive acute myeloid leukemia (AML) - Current Market Trends

CD33-positive acute myeloid leukemia (AML) - Current & Forecasted Cases across the G8 Countries

CD33-positive acute myeloid leukemia (AML) - Market Opportunities and Sales Potential for Agents

CD33-positive acute myeloid leukemia (AML) - Patient-based Market Forecast to 2035

CD33-positive acute myeloid leukemia (AML) - Untapped Business Opportunities

CD33-positive acute myeloid leukemia (AML) - Product Positioning Vis-a-vis Competitors' Products

CD33-positive acute myeloid leukemia (AML) - KOLs Insight